SCHEMBL2959707

SCHEMBL2959707

Nc1nccc(Nc2ccc(Cl)c(O)c2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 15/20 0.61
HTR3E A5X5Y0 1/20 0.61
HTR3B O95264 1/20 0.61
HTR3A P46098 1/20 0.61
HTR3D Q70Z44 1/20 0.61
HTR3C Q8WXA8 1/20 0.61
KCNH2 Q12809 1/20 0.55
SCN9A Q15858 1/20 0.55
BCL6 P41182 1/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
CA14 Q9ULX7 1/20 0.54
CA5B Q9Y2D0 1/20 0.54
MAPKAPK2 P49137 2/20 0.52
CDC7 O00311 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5308695 0.88 ROCK1 (0.61) ROCK1HTR3EHTR3BHTR3AHTR3D
SCHEMBL3038065 0.82 KDR (0.58) ROCK1HTR3EHTR3BHTR3AHTR3D
SCHEMBL5306034 0.79 ROCK1 (0.55) ROCK1HTR3EHTR3BHTR3AHTR3D
SCHEMBL31337029 0.78 SCN9A (0.82) ROCK1HTR3EHTR3BHTR3AHTR3D
SCHEMBL3044816 0.77 SCN9A (0.61) KCNH2SCN9A
SCHEMBL12813346 0.76 ROCK1 (1.00) ROCK1HTR3EHTR3BHTR3AHTR3D
SCHEMBL27612768 0.76 SYK (0.70) ROCK1HTR3EHTR3BHTR3AHTR3D
SCHEMBL3038970 0.74 PIM1 (0.52)
SCHEMBL10269737 0.71 MAPKAPK2 (0.65) ROCK1HTR3EHTR3BHTR3AHTR3D
SCHEMBL10268659 0.71 MAPKAPK2 (0.65) ROCK1HTR3EHTR3BHTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018209-B2 Compounds and methods for the treatment of viruses and cancer YALE UNIVERSITY (US) 2015-04-28 US disclosed
EP-2231185-A1 METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS Elan Pharmaceuticals Inc. (US) 2010-09-29 EP disclosed
US-20100222352-A1 Compounds and Methods for the Treatment of Viruses and Cancer YALE UNIVERSITY (US) 2010-09-02 US disclosed
WO-2009075806-A1 METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS ELAN PHARMACEUTICALS, INC. (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222352-A1 Compounds and Methods for the Treatment of Viruses and Cancer RCOR1, RCOR3, CCNT1 ROCK1 1934/4885HTR3E 2535/4885HTR3B 2836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.